SG Americas Securities LLC acquired a new stake in shares of Personalis, Inc. (NASDAQ:PSNL – Free Report) in the fourth quarter, Holdings Channel reports. The fund acquired 10,829 shares of the company’s stock, valued at approximately $63,000.
A number of other hedge funds also recently bought and sold shares of PSNL. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in Personalis by 42.5% during the third quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company’s stock valued at $81,000 after buying an additional 4,504 shares in the last quarter. nVerses Capital LLC acquired a new position in shares of Personalis in the 3rd quarter valued at about $40,000. International Assets Investment Management LLC increased its holdings in shares of Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company’s stock valued at $113,000 after purchasing an additional 17,082 shares during the period. Semanteon Capital Management LP acquired a new position in shares of Personalis in the 3rd quarter valued at about $375,000. Finally, ARK Investment Management LLC increased its holdings in shares of Personalis by 11.4% in the 3rd quarter. ARK Investment Management LLC now owns 7,085,523 shares of the company’s stock valued at $38,120,000 after purchasing an additional 723,637 shares during the period. 61.91% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
PSNL has been the topic of a number of research reports. HC Wainwright dropped their target price on Personalis from $11.00 to $8.00 and set a “buy” rating on the stock in a report on Monday, January 27th. Needham & Company LLC reiterated a “buy” rating and issued a $7.25 target price on shares of Personalis in a report on Wednesday, January 8th. Finally, Lake Street Capital upped their target price on Personalis from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, January 8th.
Personalis Stock Performance
NASDAQ:PSNL opened at $4.99 on Friday. The stock’s 50 day moving average price is $5.21 and its 200 day moving average price is $4.91. Personalis, Inc. has a 52 week low of $1.13 and a 52 week high of $7.20. The company has a market capitalization of $352.54 million, a P/E ratio of -2.97 and a beta of 1.73.
About Personalis
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
- Five stocks we like better than Personalis
- How to Choose Top Rated Stocks
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Compound Interest and Why It Matters When Investing
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- How to Plot Fibonacci Price Inflection Levels
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis, Inc. (NASDAQ:PSNL – Free Report).
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.